Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks
Open Access
- 31 October 2023
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (2) , 217-229
Abstract
Summary: Background: Patients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles.Aim: To evaluate how these changes affect cardiovascular risk.Methods: This pooled analysis, based on two large prospective studies, evaluated fasting lipid profiles of patients with CHB who were treated with TAF 25 mg/day or TDF 300 mg/day for 96 weeks. Patients who fulfilled the American College of Cardiology criteria (age 40–79 years, high‐density lipoprotein [HDL] 20–100 mg/dL, total cholesterol [TC] 130–320 mg/dL and systolic blood pressure 90–200 mmHg) required to assess 10‐year atherosclerotic cardiovascular disease (ASCVD) risk with baseline lipid data and at least one post‐baseline measurement were included in the ASCVD‐risk population. The 10‐year ASCVD risk was calculated for patients in this population, and changes from baseline to Week 96 were assessed using intermediate‐ (≥7.5%) and high‐risk (≥20%) cut‐offs.Results: Among 1632 patients, 620 (38%) met the criteria for the ASCVD‐risk population. At Week 96, fasting levels of all lipids, except TC:HDL ratio, were lower with TDF than TAF. No significant increase was observed in overall ASCVD risk or in any ASCVD‐risk categories during the 96‐week treatment period compared with baseline. A similar proportion of patients in the TAF and TDF treatment groups (1.3% and 2.3%, respectively; p = 0.34) reported cardiovascular events.Conclusion: Despite on‐treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks.Keywords
Funding Information
- Gilead Sciences
This publication has 32 references indexed in Scilit:
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infectionJournal of Hepatology, 2018
- Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort StudyGastroenterology, 2017
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis BCurrent Medical Research and Opinion, 2016
- Association between hepatitis B and metabolic syndrome: Current state of the artWorld Journal of Gastroenterology, 2016
- The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled TrialClinical Infectious Diseases, 2015
- Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionJournal of Hepatology, 2015
- Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinationsAlimentary Pharmacology & Therapeutics, 2014
- Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriersJournal of Gastroenterology and Hepatology, 2013
- Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus InfectionJournal of Clinical Oncology, 2012